Related Experiment Videos
Allogeneic bone marrow transplantation for multiple myeloma
1Division of Bone Marrow Transplantation, University of South Florida College of Medicine, Tampa 33612.
Seminars in Oncology
|October 1, 1993
Summary
Allogeneic bone marrow transplantation offers a potential cure for multiple myeloma, achieving long-term survival in 40% of patients. Early consideration is recommended for high-risk cases despite associated risks.
Area of Science:
- Hematology
- Oncology
- Transplantation Medicine
Background:
- Multiple myeloma is a hematologic malignancy with limited curative options.
- Allogeneic bone marrow transplantation (BMT) is recognized for its potential to cure multiple myeloma.
Purpose of the Study:
- To evaluate the efficacy and outcomes of allogeneic bone marrow transplantation for multiple myeloma.
- To inform treatment decisions for patients with high-risk multiple myeloma.
Main Methods:
- Review and analysis of recently published clinical trials on allogeneic BMT for multiple myeloma.
- Assessment of long-term survival rates and evidence of residual disease.
Main Results:
- Allogeneic BMT demonstrates a 40% long-term survival rate in multiple myeloma patients.
- A significant proportion of patients achieve no evidence of residual disease post-transplant.
Conclusions:
- Allogeneic bone marrow transplantation is a viable curative strategy for multiple myeloma.
- Despite risks like myelosuppression and graft-versus-host disease, early BMT should be considered for high-risk multiple myeloma patients.